Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Oncolytics Biotech Inc
ONCY
Primary Symbol:
T.ONC
Healthcare
Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and...
adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:ONC)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
(617)
•••
Lesalpes29
X
View Profile
View Bullboard History
Comment by
Lesalpes29
on Oct 15, 2024 7:12am
RE:RE:U.S. Trading today
Yes a halt and a buyout. Time to see the end of this story. Unfortunately it's probably only a dream that we share! Have a great fast!
(216)
•••
13X2413
X
View Profile
View Bullboard History
Comment by
13X2413
on Oct 14, 2024 3:06pm
RE:RE:U.S. Trading today
So would winning the lottery. Which one has the better odds?
Level Up Your Trading with BMO InvestorLine’s Enhanced Features
posted Nov 24, 2024 9:00am by
Bank of Montreal
-
|
Features like Multi-Leg Orders, Options Screener, and Strategy Builder will be particularly exciting for traders. They have been designed to be intuitive and user-friendly, regardless of your experience level. Whether you’re a seasoned pro or just starting out, you’ll find these tools easy to navigate and adapt to your investing style. ...read more
(137)
•••
fasttrack5
X
View Profile
View Bullboard History
Comment by
fasttrack5
on Oct 14, 2024 2:51pm
RE:U.S. Trading today
Would be great to see a halt for news tomorrow am. just sayin:)
(207)
•••
Buckhenry
X
View Profile
View Bullboard History
Comment by
Buckhenry
on Oct 14, 2024 2:43pm
RE:RE:RE:RE:ATRA
I love a stock that is predictable... easy to make money both ways... we are all here to make money.. Right... except fir the pumpers.. who say price does not matter. Geez
...more
(5346)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Oct 14, 2024 2:33pm
RE:RE:RE:ATRA
Correct US$8.22
(216)
•••
13X2413
X
View Profile
View Bullboard History
Comment by
13X2413
on Oct 14, 2024 2:30pm
RE:RE:RE:ATRA
What's a decimal point amongst friends?
(137)
•••
fasttrack5
X
View Profile
View Bullboard History
Comment by
fasttrack5
on Oct 14, 2024 2:27pm
RE:RE:ATRA
Correction Nitable $8.22 not $82.
(216)
•••
13X2413
X
View Profile
View Bullboard History
Post by
13X2413
on Oct 14, 2024 1:52pm
U.S. Trading today
Looks like tomorrow's going to be another bummer. Down app. 10% on almost a million shares.
(5346)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Oct 14, 2024 1:44pm
RE:ATRA
Atara is a preclinical/Phase 1 allogeneic CAR-T cell company that develops allogeneic products on a EBV-T cell backbone. I have already posted that allogeneic CAR-T cell companies are having
...more
(137)
•••
fasttrack5
X
View Profile
View Bullboard History
Post by
fasttrack5
on Oct 14, 2024 1:15pm
ATRA
Competition??? https://finance.yahoo.com/news/atara-biotherapeutics-inc-reports-inducement-200100759.html
(5346)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Oct 14, 2024 1:04pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustion
From ONCY's October 2024 slide deck: Slide #37 Why Did Avelumab Eliminate the Benefit of Pelareorep? - Avelumab is the only licensed anti- PD-L1 Ab with a native Fc region that retains
...more
(5346)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Oct 14, 2024 12:46pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustion
Transgene's failure with Bavencio (avelumab) serves to confirm ONCY's findings in ONCY's Phase 2 Bracelet-1 clinical study in metastatic breast cancer.
(5346)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Oct 14, 2024 12:41pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustion
Unlike atezolizumab, pela’s clinical activity was lost when combined with avelumab, a PD-LI inhibitor with a native Fc region that is capable of binding Fc receptors and inducing ADCC. The addition of
...more
(5346)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Oct 14, 2024 12:23pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustion
October 14, 2024 - Transgene’s therapeutic oncolytic virus / vaccine candidate TG4001when combined with the activated/native Fc checkpoint inhibitor Bavencio (avelumab) failed in their Phase 2
...more
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >